Figure 2.
Sustained virologic response at week 12 post-treatment (SVR12) in the study population based on (A) age; (B) genotypes; (C) treatment regimen; and (D) liver stage and treatment history. EBR, elbasvir; GZR, grazoprevir; OBV/PTV/r/DSV, ombitasvir/paritaprevir/ritonavir/dasabuvir; RBV, ribavirin; SOF, sofosbuvir; DCV, daclatasvir; ASV, asunaprevir; VEL, velpatasvir.